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AbstrAct
Introduction Type 2 diabetes (T2D) and heart failure 
(HF) are a frequent combination, where treatment options 
remain limited. There has been increasing interest around 
the sodium–glucose cotransporter 2 (SGLT2) inhibitors and 
their use in patients with HF. Data on the effect of SGLT2 
inhibitor use with diuretics are limited. We hypothesise that 
SGLT2 inhibition may augment the effects of loop diuretics 
and the benefits of SGLT2 inhibitors may extend beyond 
those of their metabolic (glycaemic parameters and weight 
loss) and haemodynamic parameters. The effects of 
SGLT2 inhibitors as an osmotic diuretic and on natriuresis 
may underlie the cardiovascular and renal benefits 
demonstrated in the recent EMPA-REG study.
Methods and analysis To assess the effect of SGLT2 
inhibitors when used in combination with a loop diuretic, 
the RECEDE-CHF (Renal and Cardiovascular Effects 
of SGLT2 inhibition in combination with loop Diuretics 
in diabetic patients with Chronic Heart Failure) trial is 
a single-centre, randomised, double-blind, placebo-
controlled, cross-over trial conducted in a secondary 
care setting within NHS Tayside, Scotland. 34 eligible 
participants, aged between 18 and 80 years, with stable 
T2D and CHF will be recruited. Renal physiological testing 
will be performed at two points (week 1 and week 6) on 
each arm to assess the effect of 25 mg empagliflozin, 
on the primary and secondary outcomes. Participants 
will be enrolled in the trial for a total period between 
14 and 16 weeks. The primary outcome will assess the 
effect of empagliflozin versus placebo on urine output. 
The secondary outcomes are to assess the effect of 
empagliflozin on glomerular filtration rate, cystatin C, 
urinary sodium excretion, urinary protein/creatinine ratio 
and urinary albumin/creatinine ratio when compared with 
placebo. 
Ethics and dissemination Ethics approval was obtained 
by the East of Scotland Research Ethics Service. Results 
of the trial will be submitted for publication in a peer-
reviewed journal.
trial registration number NCT03226457; Pre-results. 
bAckground
Chronic heart failure (CHF) and type 2 
diabetes (T2D) frequently coexist. In popu-
lation-based studies and in CHF trials, the 
prevalence of T2D among patients with symp-
tomatic heart failure (HF) is estimated to be 
between 12% and 41%.1 T2D has consistently 
been shown to be an independent predictor 
of increased morbidity and mortality in 
patients with CHF.2
For most patients, metformin is the first 
choice antidiabetic drug in all patients with T2D 
including those with coincidental HF.3 However, 
metformin alone is often not enough to keep 
glycaemia under control and there is a frequent 
need for a second-line antidiabetic drug in 
patients with HF. Sulfonylureas (SUs) are 
commonly prescribed in T2D; however, they are 
associated with weight gain and hypoglycaemia, 
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Protocol
strengths and limitations of this study
 ► Original proof of concept study that aims to explore 
the effect on diuresis and natriuresis of sodium–
glucose cotransporter 2 inhibitors in combination 
with furosemide.
 ► Randomised, double-blind cross-over study design.
 ► Small and single-centre study.
 ► High participant dropout rate has been factored into 
power calculations.
 ► Aims to shed light on the mechanism of the 
cardiovascular benefits seen in EMPA-REG 
OUTCOME trial.
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while there remain concerns that SUs may increase all-cause 
and cardiovascular (CV) mortality,4 although this link is not 
fully established. Glitazones are contraindicated in New York 
Heart Association (NYHA) III or IV HF, while their role in 
milder degrees of HF remains to a certain extent contro-
versial with some observational studies indicating increased 
hospitalisation or readmission due to HF.5 Insulin use has 
also been associated with increased mortality in patients 
with CHF.6 More recent agents such as the dipeptidyl pepti-
dase-IV (DPP-IV) inhibitors have also, disappointingly, failed 
to show CV benefit with some concerns raised following 
the publication of SAVOR-TIMI-53, that they increased HF 
hospitalisations, although these trials have only been of 
short duration7 and may not apply to all DPP-IV inhibitors. 
Therefore, it can be concluded that therapeutic options in 
diabetes mellitus (DM) and HF are limited due to a lack of 
evidence-based guidelines on the optimal management of 
such patients. Indeed, international guidelines recognise the 
evidence gap on the safety and efficacy of drugs used to treat 
DM in patients with HF as well as the need for agents that will 
both improve overall glycaemic control and HF outcomes.8
sgLt2 inhibitors and HF
SGLT2 inhibitors are licensed for use in patients with 
T2D. These oral antidiabetic agents achieve their effects 
by blocking the low affinity, high capacity type 2 sodium–
glucose linked cotransporter (SGLT2), predominantly 
found in the proximal convoluted tubules of the kidneys, 
thus causing glycosuria. The recent landmark EMPA-REG 
outcome study reported a striking 35% relative risk 
reduction in HF hospitalisations with empagliflozin may 
provide supportive evidence for beneficial effects of 
SGLT2 inhibition in the setting of CHF.9 A recent anal-
ysis of the EMPA-REG study showed that empagliflozin 
reduced HF hospitalisation and CV death, with a consis-
tent benefit in patients with and without baseline HF.10
The mechanisms behind the beneficial effects of 
empagliflozin on HF and CV death are unknown.9 
However, given that these effects were seen early in the 
EMPA-REG trial this would suggest that the effect was not 
caused simply by altering the atherosclerotic process.10
It has been hypothesised that the benefits of SGLT2 
inhibitors extend beyond those of the glycaemic param-
eters of weight loss as promoted by glycosuria, but the 
effects of SGLT2 inhibitors on non-glycaemia parame-
ters including blood pressure lowering as well as osmotic 
diuretic and natriuretic effects which may underlie the 
CV (and renal) benefits.11 12
renal effects of sgLt2 inhibition and coprescribing with loop 
diuretics
The renal effects of SGLT2 inhibitors are attracting much 
recent interest as they may confer renal protection.13 14 
There are data to support the potential for direct renopro-
tective actions arising from SGLT2 inhibition including 
actions to attenuate T1D associated hyperfiltration through 
an effect on tubuloglomerular (TG) feedback which may 
have renal protective effects by decreasing glomerular 
hydrostatic pressure.13 14 SGLT2 inhibition has also been 
shown to attenuate tubular hypertrophy and reduce the 
tubular toxicity of glucose.15 They may also have indirect 
renoprotective effects through its blood pressure lowering 
effects and glycaemia lowering effects which could decrease 
the renal inflammatory and fibrotic response by blocking 
glucose entry into the cell.15 Consequently, there are now 
several ongoing SGLT2 inhibitor renal outcome trials in 
T2D, including the CANVAS-R trial ( clinicaltrials. gov identi-
fier NCT01989754) and the CREDENCE trial ( clinicaltrials. 
gov identifier NCT02065791). However, neither trial specif-
ically looks at T2DM patients with CHF.
Studies relating to diuresis in the context of SGLT2 inhib-
itors are surprisingly sparse.12 Previous studies with empagli-
flozin and canagliflozin have demonstrated a 24 hours 
urinary increase by 300 mL/day after day 1 of treatment 
but that the daily urinary volume returned to baseline after 
several weeks.16 17 One Japanese case report however, in a 
non-diabetic patient, described successful treatment of fluid 
overload that was initially resistant to diuretic therapy, with 
5 days of treatment of 50 mg ipragliflozin.18
In post hoc analysis of EMPA-REG OUTCOME, Fitchett 
et al reported reduced use of furosemide in patients on the 
empagliflozin arm, suggesting that these patients reached a 
relative state of euvolaemia.10 12 Heerspink et al highlighted 
that, volume depletion and associated use of loop diuretic is 
long associated with a prerenal cause of acute kidney injury, 
and a decrease in loop diuretic may also be relevant in light 
of the reductions in acute kidney injury, acute renal failure 
and chronic kidney disease progression endpoints.12 19
The renal effects of SGLT2 inhibitors in combination 
with furosemide in T2D with CHF are not known but 
given the relative frequency of both comorbidities they 
are likely to be prescribed concurrently. This underscores 
the need for a trial to provide detailed acute and long-
term information regarding the renal effects of SGLT2 
inhibition in combination with loop diuretics, in patients 
with T2D and stable CHF.
We hypothesise that SGLT2 inhibitors may be able to 
address the issue of diuretic resistance and may augment 
the diuretic effects of furosemide in patients with T2D and 
CHF.
We will recruit patients with diabetic HF taking stable 
doses of furosemide, or, alternative loop diuretics, with 
estimated glomerular filtration rate (eGFR) greater than 
45 mL/min/1.73 m2. This trial will, with careful moni-
toring, begin the process of uncovering the unrealised 
potential of this new class of drug which, for the reasons 
outlined above, is poised to become the second-line anti-
diabetic agent of choice in patients with HF.
MEtHods: pArtIcIpAnts, IntErvEntIons And outcoMEs
trial design
The RECEDE-CHF (Renal and Cardiovascular Effects 
of SGLT2 inhibition in combination with loop Diuretics 
in diabetic patients with Chronic Heart Failure) trial 
is a single-centre phase IV, randomised, double-blind, 
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Figure 1 RECEDE-CHF (Renal and Cardiovascular Effects of SGLT2 inhibition in combination with loop Diuretics in diabetic 
patients with Chronic Heart Failure) trial design. 
placebo-controlled, cross-over trial conducted in NHS 
Tayside, Scotland, to compare the SGLT2 inhibitor 
empagliflozin 25 mg with placebo. Participants will be 
enrolled in the trial for a period of between 14 and 16 
weeks. The trial design is summarised in figure 1 and 
table 1.
At the screening visit, following informed consent, an 
initial medical history and clinical examination will be 
performed and concomitant medication will be recorded. 
Participants will have bloods taken for safety analysis and 
vital signs will be checked to confirm eligibility prior to 
enrolment. An assessment of suitability of the trial for the 
potential participant will be undertaken by the principal 
investigator (PI) or medically qualified delegate.
Should the participant meet the inclusion criteria and 
have no exclusion criteria identified, they will return for 
the baseline/randomisation visit at the Clinical Research 
Centre (CRC), Ninewells Hospital, Dundee, within 
4 weeks postscreening visit. Where able the screening visit 
and randomisation visits will be combined.
At the randomisation visit participants will undergo 
safety blood tests, vital signs and study medication will be 
dispensed (either empagliflozin 25 mg or placebo).
Participants will continue on study medication, 
empagliflozin 25 mg or placebo, once daily, for a period 
of 6 weeks. Participants will be educated on the symptoms 
of hypoglycaemia and given a written action plan on how 
to manage it in the unlikely event that it occurs.
Participants will return to the CRC 3 days (±2 days) post 
randomisation, for a study day where they will have safety 
and research bloods drawn, vital signs recorded and will 
undergo renal physiological tests (RPTs). Further details 
of these RPT are described below.
Participants will then return again at week 6 for a 
study day where they will undergo RPT again, safety and 
research bloods will be drawn and vital signs recorded. 
Participants will terminate the study drug, either empagli-
flozin 25 mg or placebo, at this visit and will return to the 
CRC at the end of the 2-week washout period (week 9).
At week 9, participants will have safety and research 
bloods drawn, vital signs recorded, and new study medi-
cation dispensed. The RPT will then be repeated at the 
same intervals, at week 9+3 days (±2 days) and at week 14 
for the final study day. Participants will then terminate 
study drug, either empagliflozin 25 mg or placebo.
study population
Thirty-four patients with underlying diabetes and 
well-controlled CHF will be recruited from a range 
of sources. The local Tayside database of the systems 
biology study to tailored treatment in CHF (BIOSTAT) 
database consisting of around 1800 patients with HF 
who have previously consented to be approached for 
future research. The investigators may also recruit from 
NHS Tayside diabetes and/or HF clinics, and SHARE 
The Scottish Health Research Register, where partici-
pants have preconsented to be invited for research. It is 
anticipated it will take up to 18 months to recruit the 34 
patients for randomisation with approximately 80–100 
being consented into the screening trial. We anticipate 
a screen failure rate of 20% and a dropout rate of 35% 
after recruitment based on previous HF studies within 
this research group and the high intensity of the RPT days 
which will occur on four occasions in total.
Eligibility
Patients will be eligible if they:
 ► Aged 18–80 years with previously diagnosed T2DM;
 ► Are diagnosed with NYHA Functional class II–III 
HF with prior echocardiographic evidence of left 
ventricular systolic dysfunction (LVSD);
 ► On stable doses of furosemide, or alternative loop 
diuretic for 1 month;
 ► Stable T2D (HbA1c, in the last 3 months, of 6.5 % ≤ 
and ≤10.0%);
 ► Point-of-care B-type natriuretic peptide (BNP) 
>100 pg/mL;
 ► eGFR ≥45 mL/min/1.73 m2;
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 ► Have stable HF symptoms for at least 3 months prior 
to consent;
 ► On stable HF therapy for at least 3 months prior to 
consent;
 ► Have not been hospitalised for HF for at least 3 months 
prior to consent.
Patients will be excluded if they:
 ► A diagnosis of chronic liver disease and/or liver 
enzymes that are twice the upper limit of normal;
 ► Systolic BP of <95 mm Hg at screening visit;
 ► eGFR <45 mL/min/1.73 m2;
 ► Patients on thiazide diuretics;
 ► Malignancy (receiving active treatment) or other life 
threatening disease;
 ► Pregnant or lactating women;
 ► Patients with difficulty in micturition, for example, 
severe prostate enlargement;
 ► Patients who have participated in any other clinical 
trial of an investigational medicinal product within 
30 days;
 ► Patients who are unable to give informed consent;
 ► Any other reason considered by the physician to be 
inappropriate for inclusion.
randomisation and treatment allocation
After successful screening for eligibility and safety, partic-
ipants will be randomised to either empagliflozin 25 mg/
placebo or placebo/empagliflozin 25 mg in a double 
blind fashion in this cross-over study.
The double-blind medication (empagliflozin or 
placebo) will be prepared, packaged and labelled by our 
onsite clinical trials pharmaceutical manufacturer. Rando-
misation will be carried out by our dedicated clinical 
trials pharmacy using block randomisation. They will use 
a validated randomisation programme and will securely 
backup both the randomisation seed and the randomisa-
tion allocation and have it available in the onsite 24 hours 
emergency unblinding facility.
Participants will be given blinded medication. At the 
randomisation visit they will be dosed with either empagli-
flozin 25 mg (6 weeks) or matched placebo (6 weeks) to 
continue once daily, with a 2 week washout period between 
each arm. Participants and their bloods (including urea 
and electrolytes, liver function tests and full blood count) 
will be monitored as per trial schedule and medication 
stopped if concerns arise. If the trial drug needs to be 
stopped due to intolerance or adverse events (AEs), they 
will remain in the trial in order to do an ‘intention to 
treat’ analysis.
trial outcomes
The primary aim/objectives will be to assess whether 
empagliflozin (SGLT2 Inhibitor) can augment the 
diuretic effects of loop diuretics in diabetic patients with 
mild CHF with LVSD, as measured by urinary volume, 
compared with placebo.
The secondary aims/objectives are to assess the effect 
of empagliflozin (SGLT2 inhibitor) on natriuresis when 
used with loop diuretics in diabetic patients with mild 
CHF with LVSD as measured by urinary sodium excretion, 
to measure the safety of add-on SGLT2 inhibitor therapy 
versus placebo on top of loop diuretics as measured by 
serum creatinine and eGFR, to assess effects of empagli-
flozin on protein/creatinine ratio, albumin/creatinine 
ratio and on the renal biomarker, cystatin C.20
renal physiology tests
Patients will attend the CRC, Ninewells, Dundee on four 
separate study days (two while in each arm of the trial). On 
each study day, patients will present themselves to our CRC, 
following an overnight fast. Two days before presenting to 
the CRC, patients will be required to follow a 2 g sodium 
and 2 L fluid/day controlled diet. A 24 hours urinary collec-
tion will be requested the day prior to presentation at the 
CRC for urinary volume and sodium. Patients will be asked 
to take their morning usual medications except their investi-
gational medicinal product (empagliflozin or placebo) and 
furosemide (or equivalent loop diuretic).
An intravenous cannula will be placed in each arm for 
subsequent infusion and blood sampling. Bloods will be 
drawn for measurement of plasma N-terminal proBNP 
and cystatin C using standard protocols. A 15 mL/kg oral 
water load will be administered over a 15 min period. 
Thereafter, at 30 min intervals, patients will be requested 
to void urine until the end of the study period. The 
volume of urine passed will be measured and an aliquot 
stored for later analysis. On each occasion, the volume 
of urine passed will be measured, and an equal volume 
of water given to drink. In this way, a steady state diuresis 
will be established over approximately over 3 hours, 
avoiding the need for catheterisation. The last 30 min 
urinary collection during this stabilisation period will be 
taken as baseline. At +150 min, each patient will receive 
an oral tablet of either empagliflozin 25 mg or placebo. 
At +210 min, patients will be given a bolus of intravenous 
furosemide at half their total daily dose.
Heart rate and blood pressure will be displayed contin-
uously on an ECG oscilloscope and the blood pressure 
measured every 60 min. Venous blood will be obtained at 
the midpoint of each clearance period for measurement 
of serum sodium, osmolality and creatinine. Figure 2 
outlines the protocol for the RPT test day.
Intravenous furosemide will be administered to elimi-
nate variable furosemide gut absorption and for practical 
reasons to complete the study within the set time frame 
due to the reduced time for the peak onset of diuretic 
effect with intravenous administration.
Data on the effect of SLGT2 inhibitors and the partici-
pant’s usual oral diuretic regime will be gained by the collec-
tion of 24 urinary samples on the days before the RPT.21
tolerability
We will monitor for tolerability of the study medication. 
One of the inevitable side effects of empagliflozin and 
other SGLT2 inhibitors with the promotion of glycosuria 
is urinary tract infections. This typically presents itself as 
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Figure 2 Protocol for renal physiology test days.
genital mycotic infection, typically Candida albicans, which is 
usually straightforward to treat. However, if patients were to 
present with infection unresponsive to standard treatment 
then the trial drug would be discontinued. They will also 
be warned of the side effects including hypoglycaemia with 
a written action plan on how to recognise and treat in the 
unlikely event of a hypoglycaemic episode.
sample size and power calculations
Power calculations were performed by the University of 
Dundee’s Senior Medical Statistician and are based on 
our previous data in patients with CHF21 as well as more 
contemporary data.22 The sample size is based on the 
mean furosemide-induced urinary volume and sodium 
excretion of 920 mL/hour (SD=250) and 300 µmol/min 
(SD=60) respectively. A 20% increase is expected in these 
parameters following SGLT2 inhibition. This increase 
in urinary volume is based on published percentage 
increases in urinary volume in patients with T2D that 
range from 11% to 33% depending on the dose of the 
SGLT2 inhibitor as shown by List and colleagues23 in the 
available data with dapagliflozin (dapagliflozin 2.5 mg: 
11% increase in 24 hours urine volume; dapagliflozin 
5 mg: 22%–11% increase in 24 hours urine volume; 
dapagliflozin 10 mg: 24%–11% increase in 24 hours 
urine volume; dapagliflozin 20 mg: 27%–11% increase 
in 24 hours urine volume and dapagliflozin 50 mg: 
33%–11% increase in 24 hours urine volume). There is 
no data of SGLT inhibition together with loop diuretics. 
As described previously the Japanese case report of a 
patient with diuretic-resistant HF in whom fluid overload 
was successfully treated with the SGLT2 inhibitor, ipragli-
flozin, where a striking 50% increase in urinary volume 
(following treatment with 50 mg daily of oral ipragliflozin 
for 5 days) was described.18 Based on the above, it was 
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determined that a 20% increase in furosemide induced 
increase in urinary volume and sodium excretion will be 
reasonable.
With an alpha 0.05 and power of 90%, 22 participants 
per arm are required, assuming 35% dropout. Since this 
trial is using an AB/BA cross-over design, a total of 34 
participants will be required, as each participant will be 
exposed to both arms of the trial. The rationale for the 
high dropout rate is due to the high intensity RPTs that 
will occur on four occasions for the participants, from 
09:00 to 14:00 hours we feel that anything less than a 35% 
dropout rate would be conservative.
MEtHods: dAtA coLLEctIon, MAnAgEMEnt And AnALysIs
data collection
The data will be collected by the PI or delegate on a 
paper case report form (CRF) with subsequent transcrip-
tion to an electronic CRF. Electronic storage will be in 
an encrypted form on a password protected device. The 
medical notes will act as source data for medical history 
and blood results. Any data relating to general medical 
history will be documented in the notes.
statistical plan
Participants will be allocated to treatment groups at 
random. Descriptive statistics will be calculated for all 
data and reported as mean (SD) for continuous data and 
n (%) for categorical data. For statistical evaluation of 
repeated measurements, analysis of variance will be used. 
p<0.05 will be taken as the level of statistical significance. 
The study is powered based on the primary outcome. In 
order to examine differences in patient characteristics 
between study groups, between-group comparisons will be 
assessed using independent t-tests or analysis of variance 
(ANOVA). Within-group comparisons will be conducted 
using paired sample t-tests or repeated-measures ANOVA 
if data meet parametric assumptions.
MEtHods: MonItorIng
data monitoring
A data monitoring committee is not considered neces-
sary as this is a relatively small trial. Close supervision of 
the PI/clinical research fellow will be conducted by an 
experienced chief investigator supported by a senior trial 
manager from the Tayside Clinical Trials Unit.
The purposes of trial monitoring are to verify that the 
rights and well-being of human subjects are protected, 
the reported trial data are accurate, complete and 
verifiable from source documents and the conduct of 
the trial is in compliance with the currently approved 
protocol/amendment(s), with good clinical practice 
and with the applicable regulatory requirement(s). 
The Sponsor will determine the appropriate extent 
and nature of monitoring for the trial and will appoint 
appropriately qualified and trained monitors. The 
monitor will communicate any monitoring findings to 
both the CI and PI and the Sponsor.
Identifying, recording and reporting AEs
Participants should be instructed to contact a member 
of the trial team at any time after consenting to join the 
trial if any of the above symptoms develop. All reported 
AEs that occur after joining the trial will be recorded 
in detail in the CRF AE log. In the case of an AE, the 
Investigator should initiate the appropriate treatment 
according to their medical judgement. Participants with 
AEs present at the last visit must be followed up until 
resolution of the event.
The CI or delegate will ask about the occurrence of AEs 
and hospitalisations at every visit during the trial. AEs will 
be recorded on the AE Log in the CRF. Serious adverse 
events (SAEs) will be submitted on an SAE form to the 
TASC Pharmacovigilance Section within 24 hours of 
becoming aware of the SAE. SAEs will be initially assessed 
for causality and expectedness by the Investigator. The 
Sponsor will make the definitive assessment on expected-
ness. The evaluation of expectedness will be made based 
on the knowledge of the reaction and the relevant product 
information (summary of product characteristics).
confidentiality
All laboratory specimens, evaluation forms, reports and 
other records will be identified in a manner designed 
to maintain participant confidentiality. All records will 
be kept in a secure storage area with limited access to 
trial staff only. Clinical information will not be released 
without the written permission of the participant, 
except as necessary for monitoring and auditing by the 
Sponsor, its designee or Regulatory Authorities. The CI 
and trial staff will not disclose or use for any purpose 
other than performance of the trial, any data, record or 
other unpublished, confidential information disclosed 
to those individuals for the purpose of the trial. Prior 
written agreement from the Sponsor or its designee will 
be obtained for the disclosure of any said confidential 
information to other parties.
Ethics and dissemination
Ethics approval was obtained by the East of Scotland 
Research Ethics Service. This trial has been funded by 
the British Heart Foundation who have peer reviewed the 
grant application. Additional peer review of the protocol 
occurs via the Sponsorship Committee.
The clinical trial report will be used for publication 
and presentation at scientific meetings. Trial investigators 
have the right to publish orally or in writing the results of 
the trial.
Prospective registration will be obtained via  clinical-
trials. gov before the enrolment of patients.
Should any protocol modifications arise, these will be 
decided by the CI on discussion with the PI, which would 
then be escalated to the trial sponsor, who will decide if 
further notification to the relevant authorities is required.
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Access to data
Ownership of the data arising from this trial resides with 
the trial team and their respective employers. On comple-
tion of the trial, the trial data will be analysed and tabu-
lated, and a clinical trial report will be prepared.
dIscussIon
SGLT2 inhibition is an innovative strategy for the manage-
ment of T2D, where historically, antihyperglycemic inter-
ventions have focused on restoring B-cell activity, insulin 
sensitivity, or tissue glucose uptake to normalise plasma 
glucose levels.12
In this proof of concept trial, we hypothesise that the 
benefits of SGLT2 inhibitors extend beyond those of 
their metabolic (glycaemic parameters and weight loss) 
and haemodynamic parameters; that the effects of SGLT2 
inhibitors as an osmotic diuretic and on natriuresis may 
underlie the CV and renal benefits.
While the encouraging renal and CV outcomes demon-
strated in EMPA-REG might be explained by the modest 
but cumulative effect of blood pressure lowering (mean 
reduction in systolic BP ~3 mm Hg), HbA1c reduction 
(0.3%), and weight reduction (~1 kg), it is difficult to 
ignore the possibility that an additional mechanism may 
also be at work.19 24 For example, Mudaliar et al hypothe-
sise that empagliflozin may also improve renal fuel ener-
getics and efficiency, providing more energy efficient 
oxygen consumption and thereby potentially less hypoxic 
stress on the diabetic heart and kidney.24
We have also described that SGLT2 inhibitors may 
augment the effect of loop diuretics. It is noteworthy that 
osmotic diuretics such as mannitol have been used alone 
or in combination with loop diuretics such as furosemide 
to promote diuresis in patients undergoing intracranial 
surgery25 and in the postoperative period to prevent 
acute kidney injury.26 In CHF, mannitol was reported to 
promote effective diuresis in a single-centre study in the 
USA.27 Importantly, in all these settings, mannitol, which 
is a potent osmotic diuretic when used in combination 
with furosemide, was shown to be safe and did not result 
in renal failure or electrolyte disturbances.
By detailing urinary volumes and sodium excretion via 
RPTs at two points 3 days and 6 weeks into the investiga-
tional medicinal product, the trial’s primary aims to assess 
the change to these markers representative of diuresis 
in patients on empagliflozin and when compared with 
placebo. The effects on natriuresis, proteinuria, albumin-
uria, cystatin C will also be studied as will the safety of 
add-on SGLT2 inhibition versus placebo.
Limitations
While power calculations have been conducted to calcu-
late the sample size, an obvious limitation is that this is a 
small single-centre trial. The proposed trial will require 
participants on four occasions to undergo detailed renal 
physiological tests, (from 09:00 to 14:00 hours) as such a 
dropout rate has been factored in of 35%.
HF is a dynamic disease; its natural history is one of the 
flux as the patient’s intravascular volume changes, their 
loop diuretic requirement may also fluctuate. However, 
as stipulated on the inclusion criteria, we will be taking 
patients with HF with evidence of previous LVSD, but with 
stable symptoms and medications for 3 months, who have 
not had a hospital admission for HF within this same time 
frame.
concLusIon
While the osmotic diuretic hypothesis11 is frequently 
discussed in relation to the renal and CV outcomes with 
SGLT2 inhibition, literature on the effect of SGLT2 inhib-
itors on diuresis is currently limited. At time of writing, no 
studies have been performed to assess the effect of loop 
diuretics when used in combination with SGLT2 inhibi-
tors. This proof of concept trial will aim to shed light on 
the mechanism of the CV and renal outcomes demon-
strated in the recent EMPA-REG study by documenting 
the influence of the SGLT2 inhibitors when used in 
combination with a loop diuretic on urinary volumes and 
natriuresis when compared with placebo.
Further intent of this proposed study is to obtain data 
that might be relevant to the design of future studies in 
which SGLT2 inhibitors may be considered as an adjunc-
tive agent to loop diuretics in patients who experience 
diuretic resistance. Although data are currently limited, 
since HF and T2D are frequent comorbidities, it is prob-
able that physicians may find patients requiring both 
SGLT2 inhibitor therapy and furosemide concurrently. 
Only by studying this, can these fundamental issues be 
addressed and, perhaps, inspire a change in practice.
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